Skip to main content

Published locations for Checkpoint inhibitor doubles 3-year survival rate of BRAF wild-type advanced melanoma

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Checkpoint inhibitor doubles 3-year survival rate of BRAF wild-type advanced melanoma

User login

  • Reset your password
  • /content/checkpoint-inhibitor-doubles-3-year-survival-rate-braf-wild-type-advanced-melanoma
  • /edermatologynews/article/178104/immuno-oncology/checkpoint-inhibitor-doubles-3-year-survival-rate
  • /fedprac/article/178104/immuno-oncology/checkpoint-inhibitor-doubles-3-year-survival-rate-braf-wild
  • /oncologypractice/article/178104/immuno-oncology/checkpoint-inhibitor-doubles-3-year-survival-rate
  • /fedprac/avaho/article/178104/immuno-oncology/checkpoint-inhibitor-doubles-3-year-survival-rate-braf
  • /hematology-oncology/article/178104/immuno-oncology/checkpoint-inhibitor-doubles-3-year-survival-rate
  • /dermatology/article/178104/immuno-oncology/checkpoint-inhibitor-doubles-3-year-survival-rate-braf